300750 CONTEMPORARY AMPEREX TECHNOLOGY CO

EQS-News: Rentschler Biopharma appoints Robert Panting as VP Global Client Program Management and Strategy

EQS-News: Rentschler Biopharma SE / Key word(s): Personnel
Rentschler Biopharma appoints Robert Panting as VP Global Client Program Management and Strategy

20.03.2025 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Rentschler Biopharma appoints Robert Panting as VP Global Client Program Management and Strategy

Laupheim (Germany) and Milford, MA, USA, March 20, 2025 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the appointment of Robert Panting, Ph.D., to the newly created position of Vice President Global Client Program Management (CPM) and Strategy, effective immediately. In this role, he will lead the company’s global Strategy initiatives and CPM functions, and he will be reporting directly to the CEO, serving as a member of the Global Leadership Team.

“As the biopharmaceutical industry evolves, aligning our client programs with our corporate strategy is essential to ensuring long-term success,” said Benedikt von Braunmühl, CEO of Rentschler Biopharma. “With increasing complexity in drug development and manufacturing, having a strong, integrated global strategic framework is key. Rob brings extensive experience in leading complex projects and aligning cross-functional teams, making him the ideal choice for this role. His leadership will be instrumental in strengthening our ability to deliver exceptional value to our clients while keeping our corporate strategy at the heart of our operations.”

In this position, Dr. Panting will be responsible for developing and driving a unified strategic roadmap, working closely with the Executive Committee and Global Leadership Team to define short-, mid-, and long-term priorities. His appointment underscores Rentschler Biopharma’s commitment to leveraging its deep expertise to create meaningful value for its clients and the patients they serve.

“I am honored to take on this role and drive our unified, forward-thinking approach that ensures continued success for our global clients,” said Dr. Robert Panting. “By integrating corporate strategy with client program management, we will enhance alignment across key functions, leverage synergies, and enable strategic initiatives that improve efficiency and client-centric execution, ensuring life-saving therapies reach the market successfully.”

Dr. Panting joined Rentschler Biopharma in 2021 as General Manager of Rentschler ATMP Ltd., where he led the establishment of a Center of Excellence for Cell and Gene Therapy. Following a strategic realignment of Rentschler Biopharma’s global business operations, which included a decision to withdraw from cell and gene therapy and intensify its focus on biologics, he transitioned into this new leadership role to drive global strategic execution. Prior to joining the company, Dr. Panting spent ten years at Fujifilm Diosynth Biotechnologies in positions of increasing responsibility in project management, client management and business planning. In his last role, Vice President for Program Management and Sales & Operations Planning, he focused on client project delivery, strategic planning, and leading major infrastructure and organizational initiatives.

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma's focus on sustainability. For further information about the company, please visit . Follow Rentschler Biopharma on .

Contact:
Rentschler Biopharma SE

Dr. Latika Bhonsle-Deeng
Global Head of Communications
Phone: 7

Media inquiries:
MC Services AG
Eva Bauer
Phone:


U.S.
Laurie Doyle
Phone:

For high-resolution images, please contact .



20.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


2103496  20.03.2025 CET/CEST

EN
20/03/2025

Underlying

300750CONTEMPORARY AMPEREX TECHNOLOGY CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEMPORARY AMPEREX TECHNOLOGY CO

 PRESS RELEASE

EQS-News: vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage

Emittent / Herausgeber: ibw – Informationszentrale der Bayerischen Wirtschaft e. V. / Schlagwort(e): Sonstiges/Sonstiges vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage 10.04.2025 / 09:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. vbw zum Koalitionsvertrag: Gute Grundlage Brossardt: „Koalitionsvertrag schafft Planungssicherheit und setzt Wachstumsimpulse“  Bertram Brossardt, Hauptgeschäftsführer der vbw – Vereinigung der Bayerischen Wirtschaft e. V.: (München, 09.04.2025). Wir freuen uns, dass jetzt der Weg frei ist f...

 PRESS RELEASE

Aquis Stock Exchange - suspension of trading

Aquis Stock Exchange Aquis Stock Exchange - suspension of trading 10-Apr-2025 / 07:00 GMT/BST The issuer is solely responsible for the content of this announcement. The following securities are suspended from trading on the Aquis Growth Market from 08.00, 10 April 2025, at the request of the company: Richmond Hill Resources Plc Ordinary Shares Symbol: SHNJ ISIN: GB00BNTBWF32 The Regulation Department Aquis Stock Exchange Floor 2, 63 Queen Victoria Street, EC4N 4UA Tel: 0203 597 6361 Email:  Website:  Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The i...

 PRESS RELEASE

EQS-News: CO2Coin one of the most successful crypto investments of the...

Issuer: Clima4Future Ltd. / Key word(s): Cryptocurrency / Blockchain/Market Launch CO2Coin one of the most successful crypto investments of the coming decades. 10.04.2025 / 04:55 CET/CEST The issuer is solely responsible for the content of this announcement.     CO2Coin is going through a phase of phenomenal growth. A year ago the price was just €1, today it is around 270 USDT - an increase in value that illustrates the enormous potential of this unique project. This development reflects the crypto community's growing interest in sustainable investments. Clima4Future Lt...

 PRESS RELEASE

EQS-News: CO2Coin eine der erfolgreichsten Krypto-Investitionen der ko...

Emittent / Herausgeber: Clima4Future Ltd. / Schlagwort(e): Kryptowährung / Blockchain/Markteinführung CO2Coin eine der erfolgreichsten Krypto-Investitionen der kommenden Jahrzehnte. 10.04.2025 / 04:55 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Der CO2Coin hat einen beeindruckenden Kursanstieg erlebt. Vor einem Jahr lag der Kurs noch bei 1 €, heute liegt er bei rund 270 USDT - eine Wertsteigerung, die das enorme Potenzial dieses einzigartigen Projekts verdeutlicht. Diese Entwicklung spiegelt das wachsende Interesse der Krypto-Com...

 PRESS RELEASE

EQS-News: Zimbabwe Government Delivers on Commitment: Compensation of ...

EQS-News: Zimbabwe Ministry of Finance, Economic Development and Investment Promotion / Key word(s): Miscellaneous Zimbabwe Government Delivers on Commitment: Compensation of Former Farm Owners under the Global Compensation Deed Commences 09.04.2025 / 20:20 CET/CEST The issuer is solely responsible for the content of this announcement. In line with the GCD agreement, the FFOs receive 1 per cent of their claim in cash, with the balance being paid through US$ denominated Treasury bonds with a 2 per cent coupon and maturities of 2 to 10 years HARARE, Zimbabwe, April 9, 2025...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch